Advanced Filters
noise

Aurora, Colorado Clinical Trials

A listing of Aurora, Colorado clinical trials actively recruiting patient volunteers.

Found 1,071 clinical trials
L Lilah Melzer, DO

Feasibility of Cough Monitoring in Children

Cystic fibrosis (CF) is a disease characterized by chronic airway infection and impaired mucociliary clearance, which predisposes those affected to recurrent pulmonary exacerbations (PEx) and progressive decline in lung function. Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) results in decreases in patient-reported cough and PEx. Despite this, increased cough remains the most common …

1 - 18 years of age All Phase N/A
J Joseph T Sakai, MD

Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder

The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting …

21 - 65 years of age All Phase N/A
K Kelly Benson-Atwood

NE3107 in Adults With Neurological Symptoms of Long COVID

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to …

18 - 69 years of age All Phase 2

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

18 years of age All Phase 1
Y Yunyan Guo

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors …

18 - 89 years of age All Phase 1/2
V Vijaya Vemulakonda, MD, JD

Decision Aid for Parents of Infants With UPJO

Ureteropelvic junction obstruction (UPJO) is the most common etiology of high-grade hydronephrosis, affecting approximately 4,000-10,000 infants annually in the U.S. The goal of surgical treatment of UPJO is to minimize the risk of kidney damage associated with obstruction, which may occur in 30-60% of infants with high-grade hydronephrosis.1-However, the benefit …

18 - 89 years of age All Phase N/A

A Study of EBC-129 in Advanced Solid Tumours

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

18 years of age All Phase 1
J John Seagrist

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.

18 - 70 years of age All Phase 1
E Eva Morava-Kozicz, MD, PhD

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

The purpose of this research is to study the natural history of congenital disorders of glycosylation and its causes and treatments.

years of age All Phase N/A
M Martha Cavallo, ANP

Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.

- 72 years of age All Phase 1

Simplify language using AI